Axsome Therapeutics Inc. | Mutual Funds
Mutual Funds that own Axsome Therapeutics Inc.
Royce Value Plus Fund
556,000
2.12%
-100,000
0.48%
06/30/2018
Fidelity Select Biotechnology Portfolio
470,252
1.79%
0
0.02%
07/31/2018
Royce Low Priced Stock Fund
332,400
1.27%
32,400
0.4%
06/30/2018
Vanguard Total Stock Market Index Fund
331,550
1.26%
0
0%
07/31/2018
Fidelity Advisor Biotechnology Fund
228,263
0.87%
-283,435
0.03%
07/31/2018
Vanguard Extended Market Index Fund
197,614
0.75%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
61,057
0.23%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
50,000
0.19%
0
0.04%
12/31/2017
iShares Micro Cap ETF
43,537
0.17%
0
0.01%
09/06/2018
Vanguard Institutional Total Stock Market Index Fund
34,549
0.13%
0
0%
07/31/2018
| Address |
200 Broadway
New York New York 10038
United States
|
|
Employees
|
- |
| Website |
http://www.axsome.com |
| Updated |
07/08/2019 |
| Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. |
